GlassScriptPhysician profile
Mark W Oldendorf
NPI 1427147800
$4,044.73
in general payments reported to CMS, 2019-2025
39 companies · $801 in 2025
The $801 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $132 · 2021: $13.70 · 2022: $662 · 2023: $1,116 · 2024: $1,057 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,975.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,974.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $529.33 | 2020-2025 | |
| Novo Nordisk INC | $517.04 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $354.87 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $345.46 | 2022-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $181.33 | 2023-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $178.25 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Exact Sciences Corporation | $155.64 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lundbeck LLC | $154.31 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $149.00 | 2023-2024 | Austedo Xr |
| Astellas Pharma US INC | $122.26 | 2022-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $120.28 | 2019-2023 | Farxiga |
| Abbott Laboratories | $98.34 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $87.27 | 2019-2025 | |
| Hologic Sales and Service, LLC | $86.23 | 2022 | |
| Janssen Pharmaceuticals, INC | $82.15 | 2023-2025 | Spravato |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $77.87 | 2019-2023 | Trelegy Ellipta |
| Indivior INC. | $76.59 | 2024-2025 | Sublocade |
| Axsome Therapeutics, INC. | $74.22 | 2023-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.78 | 2023-2025 | Jardiance |
| Idorsia Pharmaceuticals US INC | $56.81 | 2022-2024 | Quviviq |
| Sunovion Pharmaceuticals INC. | $43.06 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.28 | 2022 | |
| Braeburn INC. | $39.56 | 2025 | Brixadi |
| Amgen INC. | $38.25 | 2019-2025 | Krystexxa |
| Dexcom, INC. | $37.95 | 2022-2023 | Dexcom G6 Transmitter |
| Collegium Pharmaceutical, INC. | $34.60 | 2023-2024 | Xtampza, Belbuca |
| Orexo US, INC. | $29.47 | 2022-2025 | Zubsolv |
| Seqirus USA INC | $28.99 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $28.37 | 2023 | Contrave, Onzetra Xsail |
| Sanofi Pasteur INC. | $28.20 | 2025 | |
| Amarin Pharma, INC. | $27.65 | 2019-2020 | |
| Ibsa Pharma INC. | $25.03 | 2020-2024 | Licart, Tirosint |
| Ars Pharmaceuticals Operations, INC. | $24.90 | 2025 | Neffy |
| Corium, LLC | $22.05 | 2023 | Azstarys |
| Regeneron Healthcare Solutions, INC. | $17.97 | 2023 | Evkeeza |
| Kowa Pharmaceuticals America, INC. | $15.40 | 2024 | Zoryve |
| Allergan, INC. | $15.16 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.11 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $13.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Oldendorf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.